Advanced Radiation Centers of New York Pioneers the First Commercial U.S. Implantation of a Biodegradable Balloon Spacer That Will Revolutionize Radiation Therapy for Prostate Cancer
Retrieved on:
星期四, 十一月 2, 2023
Surgery, Men, Medical Devices, General Health, Hospitals, Science, Medical Supplies, Consumer, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Other Health, Radiology, Oncology, Solaris, American Cancer Society, Radiation therapy, IMP, Management of prostate cancer, Lung cancer, Prostate cancer, Urology, Multimedia, Death, National Directorate for Migration (Argentina), Rectum, Risk, Radiation, Collateral damage, Safety, ARC, Patient, Prostate, Medical device, Medical imaging
Prostate cancer patients treated at Advanced Radiation Centers of New York (ARC) became the first in the United States to benefit from the implantation of a novel biodegradable rectal spacer – The BioProtect Balloon Implant System.
Key Points:
- Prostate cancer patients treated at Advanced Radiation Centers of New York (ARC) became the first in the United States to benefit from the implantation of a novel biodegradable rectal spacer – The BioProtect Balloon Implant System.
- Now, rather than a gel, the novel biodegradable pre-formed saline-filled BioProtect Balloon® can create nearly double the protective space between the prostate and rectum during radiation therapy.
- There are 288,300 new cases of prostate cancer a year in the United States and 34,700 deaths from prostate cancer, according to the American Cancer Society.
- Thomas Schmidt and other men who are initial recipients of the BioProtect Balloon Spacer have non-metastatic and potentially curable prostate cancers.